Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes

Beijing Chao-yang Hospital, Capital Medical University

The intestinal microflora imbalance has been associated with obesity and type 2 diabetes. The researchers' study aimed to investigate the effect of saxagliptin on gut microbiota in patients with newly diagnosed type 2 diabetes.

Inclusion Criteria:

• Females or males, and aged 20 to 65 years.
• Newly diagnosed type 2 diabetes
• HbA1C ≥7% and HbA1C <9%

Exclusion Criteria:

• Hepatic insufficiency (ALT or AST> 1.5*ULN)
• Renal insufficiency [Creatinine clearance rate (Ccr)]<60ml/min estimated from MDRD equation)
• Coronary artery disease
• Thyroid disease
• Infectious disease
• Systemic inflammatory disease
• Cancer
• Subjects who were taking agents known to influence gut microbiota
• Pregnant or lactating woman
• Other conditions at investigator's discretion